These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 32213108)
1. Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors. Fan P; Chi X; Liu G; Zhang G; Chen Z; Liu Y; Fang T; Li J; Banadyga L; He S; Yu C; Qiu X; Chen W MAbs; 2020; 12(1):1742457. PubMed ID: 32213108 [TBL] [Abstract][Full Text] [Related]
2. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655 [TBL] [Abstract][Full Text] [Related]
3. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854 [TBL] [Abstract][Full Text] [Related]
4. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532 [TBL] [Abstract][Full Text] [Related]
5. Fully human monoclonal antibodies against Ebola virus possess complete protection in a hamster model. Li W; Yang W; Liu X; Zhou W; Wang S; Wang Z; Zhao Y; Feng N; Wang T; Wu M; Ge L; Xia X; Yan F Emerg Microbes Infect; 2024 Dec; 13(1):2392651. PubMed ID: 39155772 [TBL] [Abstract][Full Text] [Related]
6. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins. Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907 [No Abstract] [Full Text] [Related]
7. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917 [TBL] [Abstract][Full Text] [Related]
8. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE Front Immunol; 2021; 12():706757. PubMed ID: 34335620 [TBL] [Abstract][Full Text] [Related]